- Home
- HHS vs PULM Comparison
HHS vs PULM Comparison
Compare HHS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- PULM
- Stock Information
- Founded
- HHS 1923
- PULM 2003
- Country
- HHS United States
- PULM United States
- Employees
- HHS N/A
- PULM N/A
- Industry
- HHS Advertising
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- PULM Health Care
- Exchange
- HHS Nasdaq
- PULM Nasdaq
- Market Cap
- HHS 30.3M
- PULM 33.2M
- IPO Year
- HHS N/A
- PULM N/A
- Fundamental
- Price
- HHS $3.39
- PULM $6.11
- Analyst Decision
- HHS
- PULM
- Analyst Count
- HHS 0
- PULM 0
- Target Price
- HHS N/A
- PULM N/A
- AVG Volume (30 Days)
- HHS 29.7K
- PULM 57.4K
- Earning Date
- HHS 08-07-2025
- PULM 08-12-2025
- Dividend Yield
- HHS N/A
- PULM N/A
- EPS Growth
- HHS N/A
- PULM N/A
- EPS
- HHS N/A
- PULM N/A
- Revenue
- HHS $181,355,000.00
- PULM $1,921,000.00
- Revenue This Year
- HHS $6.54
- PULM N/A
- Revenue Next Year
- HHS N/A
- PULM $134.88
- P/E Ratio
- HHS N/A
- PULM N/A
- Revenue Growth
- HHS N/A
- PULM N/A
- 52 Week Low
- HHS $3.24
- PULM $1.78
- 52 Week High
- HHS $8.52
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- HHS 32.88
- PULM 37.18
- Support Level
- HHS $3.38
- PULM $6.28
- Resistance Level
- HHS $4.03
- PULM $6.83
- Average True Range (ATR)
- HHS 0.31
- PULM 0.36
- MACD
- HHS -0.02
- PULM -0.07
- Stochastic Oscillator
- HHS 0.91
- PULM 0.91
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).